SCHEMBL256037

SCHEMBL256037

O=C1CCCN1Cc1ccc(I)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.65
HRH3 Q9Y5N1 1/20 0.59
ACACB O00763 1/20 0.54
GRIA2 P42262 4/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
KCNH2 Q12809 1/20 0.45
CDC7 O00311 1/20 0.45
PLK4 O00444 1/20 0.45
AURKA O14965 1/20 0.45
MAPK13 O15264 1/20 0.45
PDPK1 O15530 1/20 0.45
DYRK3 O43781 1/20 0.45
PRKD3 O94806 1/20 0.45
MAP4K4 O95819 1/20 0.45
PAK4 O96013 1/20 0.45
ERBB2 P04626 1/20 0.45
NTRK1 P04629 1/20 0.45
PRKCG P05129 1/20 0.45
FYN P06241 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11200681 0.91 L3MBTL1 (0.76) L3MBTL1HRH3ACACBGRIA2CYP1A2
SCHEMBL10399987 0.84 L3MBTL1 (0.67) L3MBTL1HRH3ACACBGRIA2CYP1A2
SCHEMBL19717008 0.84 L3MBTL1 (0.67) L3MBTL1HRH3ACACBGRIA2CYP1A2
SCHEMBL15242991 0.83 L3MBTL1 (0.45) L3MBTL1HRH3KMT2AACHE
SCHEMBL632892 0.82 L3MBTL1 (0.65) L3MBTL1HRH3ACACBGRIA2CYP1A2
SCHEMBL6824717 0.82 L3MBTL1 (0.65) L3MBTL1HRH3ACACBGRIA2CYP1A2
SCHEMBL13853398 0.82 L3MBTL1 (0.65) L3MBTL1HRH3ACACBGRIA2CYP1A2
SCHEMBL5578262 0.82 L3MBTL1 (0.65) L3MBTL1HRH3ACACBGRIA2CYP1A2
SCHEMBL13215733 0.82 L3MBTL1 (0.65) L3MBTL1HRH3ACACBGRIA2CYP1A2
SCHEMBL3903106 0.82 L3MBTL1 (0.65) L3MBTL1HRH3ACACBGRIA2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3580213-B1 AMPA RECEPTOR POTENTIATORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2024-03-27 EP disclosed
CN-110520418-B AMPA receptor potentiators 加的夫大学学院咨询有限公司 2022-08-16 CN disclosed
US-11186567-B2 AMPA receptor potentiators UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2021-11-30 US disclosed
US-11186567-B2 AMPA receptor potentiators UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2021-11-30 US disclosed
US-20210139463-A1 AMPA RECEPTOR POTENTIATORS DRAIG THERAPEUTICS LTD (GB) 2021-05-13 US disclosed
US-20210139463-A1 AMPA RECEPTOR POTENTIATORS DRAIG THERAPEUTICS LTD (GB) 2021-05-13 US disclosed
CN-110520418-A Ampa receptor reinforcing agent UNIV SUSSEX 2019-11-29 CN disclosed
WO-2018146486-A1 AMPA RECEPTOR POTENTIATORS THE UNIVERSITY OF SUSSEX (GB) 2018-08-16 WO disclosed
EP-2611771-B1 SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2016-11-23 EP disclosed
EP-2611771-B1 SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2016-11-23 EP disclosed
WO-2008148832-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEROF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed
WO-2008148836-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed
EP-1996555-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-12-03 EP disclosed
WO-2008053031-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-05-08 WO disclosed
WO-2008053031-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-05-08 WO disclosed
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2008-02-21 US disclosed
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2008-02-21 US disclosed
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2008-02-21 US disclosed
WO-2007107539-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2007-09-27 WO disclosed
WO-2007107539-A1 COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139463-A1 AMPA RECEPTOR POTENTIATORS GRIN1, GRM1, GRM2 L3MBTL1 3921/4885HRH3 342/4885ACACB 3910/4885
US-11186567-B2 AMPA receptor potentiators GRIN1, GRM1, GRM2 L3MBTL1 3921/4885HRH3 342/4885ACACB 3910/4885
US-20080045532-A1 Compounds which potentiate AMPA receptor and uses thereof in medicine GRIN1, GRM2, GRM1 L3MBTL1 4582/4885HRH3 775/4885ACACB 2073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.